Stay updated with breaking news from Hematology Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
Bristol Myers Squibb announced the withdrawal of the sBLA for luspatercept-aamt for the treatment of anemia in adults with NTD beta thalassemia.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not ap...
Analysis of HR+/HER2- patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly 16 months.
BASEL (dpa-AFX) - Novartis (NVS) reported positive topline results from an interim analysis of the phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab